Specialty Pharmacy

JMCP has added two prominent academic health care researchers to its editorial team, a move designed to keep pace with the growing influence of AMCP’s peer-reviewed, scientific journal.

Partnership Forum: This forum made recommendations and considerations for ways that benefit design and reimbursement may evolve without compromising patient access and care.

Increased simplicity, broader financial risk sharing, and an enhanced focus on patient care were among the recommendations developed by diverse stakeholders at a recent AMCP Partnership Forum focused on how to better manage the high costs of specialty medications.

Disease management is the concept of reducing health care costs and improving quality of life for individuals with chronic conditions by preventing or minimizing the effects of the disease through integrated care. Disease management programs are designed to improve the health of persons with chronic conditions and reduce associated costs from avoidable complications by identifying and treating chronic conditions more quickly and more effectively, thus slowing the progression of those diseases.

Over the past several years, the introduction, utilization and cost share of specialty pharmacy products has been increasing at a rate substantially greater than that of other pharmaceuticals. This paper examines the characteristics of specialty pharmaceuticals; the growth of new expertise to handle and manage these pharmaceuticals; and the needs these products create for patients, health plans and practitioners.

Press Release: From News&Views April 2019: The Biologics Price Competition and Innovation Act (BPCIA) of 2009 created an FDA approval pathway for biosimilars that aimed to expanded patient access to these more affordable therapies.

Press Release: The Journal of Managed Care & Specialty Pharmacy (JMCP) is pleased to announce the addition of two experienced managed care pharmacy experts to the JMCP editorial team.